Rgenta Therapeutics
Cambridge, US · Founded 2019 · Delaware corporation · 32 employees on LinkedIn · 5 known investors
Rgenta develops orally available small molecule therapies that target RNA to address diseases previously considered undruggable, with programs in oncology (targeting proteins such as MYB in solid tumors and hematologic cancers) and central nervous system repeat expansion disorders like Huntington's disease. It operates in the RNA-targeted drug development space.
Founders & leadership
Rgenta Therapeutics was founded in 2019 by Travis Wager, Hualin Simon Xi, Zhiping Weng, and Simon Xi.
TW
Travis WagerCo-founder, President and CSO
HS
Hualin Simon XiCo-founder
ZW
Zhiping WengCo-founder
SX
Simon XiCo-founder and CEO
JW
Jackie WallingCMO
DR
Debasish RoychowdhuryNamed on SEC filing
SL
Sun LinghaoNamed on SEC filing
Board
Investors · 5
Reported raises · per SEC filings
Form D private placements$18.9M disclosed across 2 rounds · 2020–2021
▶$8.9MraisedFeb 2022 · 6 investors · OtherRule 506(b)
▶$8.9MraisedFeb 2022 · 6 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Judith LiDirector
- Sun LinghaoDirector
- Hualin Simon XiExecutive Officer, Director
- Fei ShenDirector
- Debasish RoychowdhuryDirector
- Hongbo LuDirector
- Travis WagerExecutive Officer
- Zhiping WengDirector
- Offering amount
- $8.9M
- Amount sold
- $8.9M
- First sale
- Nov 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$10MraisedMar 2021 · 6 investors · OtherRule 506(b)
▶$10MraisedMar 2021 · 6 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Judith LiDirector
- Hongbo LuDirector
- Debasish RoychowdhuryDirector
- Travis WagerExecutive Officer
- Sun LinghaoDirector
- Hualin Simon XiExecutive Officer, Director
- Zhiping WengDirector
- Martin HeideckerDirector
- Offering amount
- $38M
- Amount sold
- $10M
- First sale
- Jan 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 7
by search overlap
Orna22 shared keywordsOrna Therapeutics develops RNA and lipid nanoparticle (LNP) based therapies for treating diseases including oncology and cell therapy applications. The company leverages proprietary drug development expertise in oRNA and LNP technology platforms.
Ronatherapeutics18 shared keywordsRona Therapeutics develops siRNA-based therapeutics using its GAIA platform to target metabolic and cardiovascular conditions including hypertriglyceridemia, obesity, ASCVD, and MASH. Its pipeline includes APOC3, INHBE, PCSK9-Lp(a), and angiotensinogen-targeting candidates for patients with cardiovascular and metabolic diseases.
Regeneron NASDAQ: REGN www.regeneron.com18 shared keywordsRegeneron is a biotechnology company that develops medicines ranging from biologics to genetic medicines to treat serious diseases across areas such as metabolic disease, ophthalmology, and rare disease. The company focuses on research and development driven by human biology, with a clinical trial pipeline addressing conditions like generalized myasthenia gravis.
Bioworld17 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Orogentx17 shared keywordsOrogen Therapeutics is a drug discovery company that uses AI-enabled DNA-encoded library (DEL) technology and machine learning to identify novel small-molecule compounds targeting cytokine-related immuno-inflammatory disorders. The company focuses on developing oral small-molecule candidates for therapeutic areas including dermatology, rheumatology, and gastroenterology.
Aro Biotherapeutics16 shared keywordsAro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins. The company builds a wholly-owned pipeline of Centyrin-based therapeutic candidates and partners with industry to enable tissue-specific targeting of therapeutics across a range of diseases.
Redona16 shared keywordsRedona Therapeutics develops novel therapeutics targeting enzymes involved in the dysregulation of RNA and DNA processing and signaling, which contribute to serious diseases such as cancer and autoimmune conditions. The company operates in the biotech and drug discovery space.
Companies competing with Rgenta Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Rgenta Therapeutics do?
- Rgenta develops orally available small molecule therapies that target RNA to address diseases previously considered undruggable, with programs in oncology (targeting proteins such as MYB in solid tumors and hematologic cancers) and central nervous system repeat expansion disorders like Huntington's disease. It operates in the RNA-targeted drug development space.
- Who founded Rgenta Therapeutics?
- Rgenta Therapeutics was founded by Travis Wager, Hualin Simon Xi, Zhiping Weng, Simon Xi in 2019.
- Who are Rgenta Therapeutics's investors?
- Rgenta Therapeutics's investors include Delos Capital, Vivo Capital, AMR Action Fund, Korea Investment Partners, Lilly Asia Ventures.
- How much funding has Rgenta Therapeutics raised?
- Rgenta Therapeutics has disclosed $18.9M raised across 2 rounds.
- Where is Rgenta Therapeutics headquartered?
- Rgenta Therapeutics is headquartered in Cambridge, US.